Back to top

medical-devices: Archive

Zacks Equity Research

Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?

Robust acquisitions and a widespread distribution network bode well for Henry Schein's (HSIC) operations.

HSICPositive Net Change HAENegative Net Change MEDPNegative Net Change HIMSPositive Net Change

Zacks Equity Research

Implied Volatility Surging for AdaptHealth (AHCO) Stock Options

Investors need to pay close attention to AdaptHealth (AHCO) stock based on the movements in the options market lately.

AHCOPositive Net Change

Zacks Equity Research

Implied Volatility Surging for Labcorp (LH) Stock Options

Investors need to pay close attention to Labcorp (LH) stock based on the movements in the options market lately.

LHPositive Net Change

Zacks Equity Research

Here's Why You Should Add DaVita (DVA) to Your Portfolio

DaVita's (DVA) strength in its kidney care raises optimism about the stock.

UHSPositive Net Change ISRGNegative Net Change DVANegative Net Change DXCMNegative Net Change

Zacks Equity Research

Masimo (MASI) Gets Non-Binding Offer for Consumer Business

Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.

UHSPositive Net Change DVANegative Net Change MASIPositive Net Change DXCMNegative Net Change

Zacks Equity Research

GE HealthCare's (GEHC) New Solution to Aid Prostate Treatment

GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.

UHSPositive Net Change SYKNegative Net Change DVANegative Net Change GEHCPositive Net Change

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock for Now

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

UHSPositive Net Change SYKNegative Net Change DVANegative Net Change NVROPositive Net Change

Zacks Equity Research

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

SYKNegative Net Change DVANegative Net Change MBOTNegative Net Change ELVPositive Net Change

Zacks Equity Research

IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."

UHSPositive Net Change DVANegative Net Change DXCMNegative Net Change ICCMNegative Net Change

Zacks Equity Research

Here's How Abbott (ABT) is Placed Ahead of Q2 Earnings Release

Abbott Laboratories' (ABT) second-quarter 2024 results are likely to reflect broad-based strength across several businesses and solid progress in the pipeline.

ABTNegative Net Change HCAPositive Net Change HIMSPositive Net Change ENOVPositive Net Change

Zacks Equity Research

Baxter (BAX) Shares Rise 2.4% in July: Will It Go Higher?

Shares of Baxter (BAX) are showing signs of stability after falling in the first half of 2024. Let's see what is driving investors' sentiment for the company.

BAXNegative Net Change DXCMNegative Net Change CGPositive Net Change GKOSNegative Net Change

Zacks Equity Research

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

UHSPositive Net Change ISRGNegative Net Change DVANegative Net Change DXCMNegative Net Change

Shaun Pruitt

Top Medical Stocks to Buy for Growth & Performance

The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.

HAENegative Net Change HALOPositive Net Change NBIXPositive Net Change

Zacks Equity Research

3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

ECLNegative Net Change SYKNegative Net Change DVANegative Net Change AVTRPositive Net Change

Zacks Equity Research

Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance

Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.

ECLNegative Net Change UHSPositive Net Change DVANegative Net Change OFIXNegative Net Change

Zacks Equity Research

Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit

Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.

ECLNegative Net Change SYKNegative Net Change DVANegative Net Change MASIPositive Net Change

Zacks Equity Research

Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028

The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.

ECLNegative Net Change UHSPositive Net Change DVANegative Net Change INSPNegative Net Change

Zacks Equity Research

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.

HAENegative Net Change MYGNNegative Net Change MEDPNegative Net Change HIMSPositive Net Change

Zacks Equity Research

Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod

Olink's (OLK) buyout by Thermo Fisher gets CMA's approval, signaling regulatory confidence in the merger's compliance with competition laws.

UHSPositive Net Change DVANegative Net Change TMOPositive Net Change

Zacks Equity Research

Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?

Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.

ECLNegative Net Change UHSPositive Net Change SYKNegative Net Change DVANegative Net Change

Zacks Equity Research

Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy

Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.

DXCMNegative Net Change CRLNegative Net Change MEDPNegative Net Change HIMSPositive Net Change

Zacks Equity Research

Here's Why Holding Align Technology (ALGN) Stock Could Pay Off

Align Technology's (ALGN) Invisalign portfolio expansion efforts spark optimism.

ALGNNegative Net Change PENNegative Net Change MEDPNegative Net Change HIMSPositive Net Change

Zacks Equity Research

The Zacks Analyst Blog Highlights Thermo Fisher Scientific, Eaton, Palo Alto, Keurig Dr Pepper and Yum! Brands

Thermo Fisher Scientific, Eaton, Palo Alto, Keurig Dr Pepper and Yum! Brands are included in this Analyst Blog.

ETNNegative Net Change YUMPositive Net Change TMOPositive Net Change PANWNegative Net Change KDPPositive Net Change